Silver Book

Silver Book Fact

Cost-savings associated with optimal anticoagulation in AFib patients

If half of all atrial fibrillation patients receiving suboptimal or no anticoagulation instead received optimal anticoagulation, 28,000 strokes could be prevented each year at a savings of around $2.5 billion in direct costs.

Caro J. An Economic Model of Stroke in Atrial Fibrillation: The cost of suboptimal oral anticoagulation. Am J Managed Care. 2004; 10(14): S451-61. https://www.ajmc.com/view/dec04-1992ps451-s461

Reference

Title
An Economic Model of Stroke in Atrial Fibrillation: The cost of suboptimal oral anticoagulation
Publication
Am J Managed Care
Publication Date
2004
Authors
Caro J
Volume & Issue
Volume 10, Issue 14
Pages
S451-61
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Aspirin use in AFib patients
    Meta-analysis of a number of randomized controlled trials found that aspirin use in atrial fibrillation patients reduced stroke risk by an average 22%.  
  • Effect of optimal anticoagulation
    If 50% of atrial fibrillation patients who currently receive warfarin in routine medical care were optimally anticoagulated, 9,852 emboli would be prevented and $1.3 billion would be saved each year.  
  • Identifying individuals at high risk for developing AFib
    Using simple bedside measures, identification of individuals at risk for developing atrial fibrillation is feasible. Selecting high-risk individuals for inclusion in atrial fibrillation prevention trials may also enhance prevention strategies.  
  • Atrial fibrillation ablation prevents recurrence of AFib
    Atrial fibrillation ablation, which involves using a catheter inserted into the heart to destroy electrical conduction tissue in or near the atria, prevents the recurrence of atrial fibrillation in up…  
  • Effectiveness of pacemaker/defibrillators to control AFib
    Widespread use of pacemaker/defibrillators to control atrial fibrillation could result in a 50% decrease in stroke.